NEW YORK, Dec. 1, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17 ...

LOS ANGELES, CA / ACCESSWIRE / December 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

On Friday, Humacyte Inc (HUMA) stock saw a modest uptick, ending the day at $4.47 which represents a slight increase of $0.07 or 1.59% from the prior close of $4.4. The stock opened at $4.44 and ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your ...

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has be ...

Fox, MD, FACS, Director of Vascular Surgery at the University of Maryland Capital Region, a clinical investigator in the Humacyte V005 trauma clinical trial. "The ATEV is perfectly sized to treat most ...

The most recent trading session ended with Humacyte, Inc. (HUMA) standing at $5.46, reflecting a +0.09% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of ...

THE LAWSUIT: A class action securities lawsuit was filed against Humacyte, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between May 10, ...

DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable ...

Benchmark analyst Bruce Jackson maintained a Buy rating on Humacyte (HUMA) with a price target of $15.00, suggesting a significant upside for the company’s stock. Humacyte shares closed at $5.39 ...